In both preeclampsia and antiangiogenic tumour therapy the VEGF/PLGF pathway is either blocked by sFlt-1, therapeutic antibodies against the growth factors, or VEGF receptor inhibition. This evidence concerns the gene VEGFA and neoplasm.